Br J CancerBritish Journal of Cancer0007-09201532-1827Nature Publishing Group2853103660563210.1038/sj.bjc.6605632CorrigendumGlucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolismBeesleyA HFirthM JFordJWellerR EFreitasJ RPereraK UKeesU R3003201030032010102712001200Copyright 2010, Cancer Research UK2010Cancer Research UK

Correction to: British Journal of Cancer (2009) 100, 1926–1936; doi:10.1038/sj.bjc.6605072

In reference to Figure 4D, the drug quercetin is clearly cytotoxic as a single agent in the ALL-SIL cell line, but its effect in combination with dexamethasone (DEX) is not synergistic as originally quoted. Rather, the combination of quercetin and DEX resulted in a small, though non-significant reduction in cytotoxicity. This is in contrast to resveratrol (Figure 4E), which demonstrated synergistic cytotoxicity in combination with DEX. This difference in the two agents is reflected in their connectivity map (CMAP) enrichment scores in Table 3, with quercetin showing a positive enrichment in contrast to the negative scores for resveratrol, LY-294002 and rapamycin. Both quercetin and resveratrol are polyphenols that activate the key metabolic regulator AMPK, but the results suggest that they are mechanistically different and are unlikely to be equally efficacious in combinatorial therapy with glucocorticoids in T-cell acute lymphoblastic leukaemia (T-ALL). Figure 4D and Table 3 from the original paper are reproduced for reference, below.

Synergy of CMAP-identified drugs with DEX in T-ALL cell lines. Graphs show cell survival following 48 h incubation. Comparisons were made in each data set to the respective control condition, which was set to 100%. Vehicle control (C) and the following drug treatments were analysed: (D) 10 mM (Q10), 25 mM (Q25) quercetin and 1 mM DEX (D1) in ALL-SIL.

CMAP drugs significantly associated with MPRED- and DEX-resistance gene signatures in T-ALL cell lines

MPREDDEX
DrugMechanism of actionEnrichmentP-valueDrugMechanism of actionEnrichmentP-value
LY-294002AKT/PI3K inhibitor−0.5070.0001RapamycinmTOR inhibitor−0.653<0.0001
Trichostatin AHDAC inhibitor−0.4230.018GeldenamycinHSP90 inhibitor0.6550.004
CarbamazepineAntiepileptic−0.7920.020LY-294002AKT/PI3K inhibitor−0.3970.005
W-13Calmodulin antagonist0.9030.021Sodium phenylbutyrateHDAC inhibitor−0.5640.014
BlebbistatinMyosin II inhibitor−0.8960.023QuercetinROS scavenger/antioxidant0.9030.019
WortmanninAKT/PI3K inhibitor−0.4970.024ResveratrolROS scavenger/antioxidant−0.6300.020
BenserazideAmino-acid decarboxylase inhibitor0.8850.028Cobalt chlorideHypoxia mimetic−0.7420.037
RapamycinmTOR inhibitor−0.4410.031FludrocortisoneSteroid0.8570.042
IndomethacinCyclo-oxygenase inhibitor0.6620.031DeferoxamineHypoxia mimetic−0.7170.049
QuercetinROS scavenger/antioxidant0.8760.033    
Y-27632Rho-kinase inhibitor−0.8720.036    
TamoxifenOestrogen-receptor blocker0.7400.039    
ResveratrolROS scavenger/antioxidant−0.5830.040